Publications by authors named "M DiBonaventura"
Patients with triple-class refractory (TCR) multiple myeloma (MM) have limited treatment options and poor prognoses. This high unmet need has prompted the development of new therapies allowing for improved outcomes for these patients. Recently, new targeted therapies for the treatment of patients with relapsed or refractory MM have been approved based on single-arm clinical trial results.
View Article and Find Full Text PDFArticle Synopsis
- Relapsed or refractory multiple myeloma (RRMM) significantly affects patients' health-related quality of life (QOL), causing both physical and emotional burdens.
- An analysis of patient-reported outcomes (PROs) from the MagnetisMM-3 study on elranatamab showed early improvements in symptoms, such as reduced pain and better health outlooks for patients new to and those previously treated with BCMA therapy.
- Approximately 40.2% of BCMA-naive and 52.6% of BCMA-exposed patients reported feeling 'a little better' or 'much better' by Cycle 1, Day 15, indicating that elranatamab not only offers clinical benefits but may also enhance
Article Synopsis
- - In the MagnetisMM-3 trial, the efficacy of elranatamab was compared to physician's choice treatment for patients with triple-class refractory multiple myeloma, showing promising results for the new therapy.
- - Analysis of two oncology databases (COTA and Flatiron Health) revealed that patients treated with elranatamab had a higher objective response rate, longer progression-free survival, and better overall survival compared to those receiving standard physician-selected treatments.
- - Elranatamab demonstrated significant benefits for BCMA-naive patients, suggesting it may be a more effective option compared to treatments commonly used in clinical practice.
Background: Abrocitinib, an oral, once-daily Janus kinase 1-selective inhibitor, improved itch severity, sleep, and work productivity versus placebo in patients with moderate-to-severe atopic dermatitis.
Objective: The aim of this study was to investigate relationships among itch, sleep, and work productivity in the phase III JADE MONO-2 clinical trial.
Methods: A repeated-measures longitudinal model was used to examine relationships between itch (using the Peak Pruritus Numerical Rating Scale [PP-NRS] or Nighttime Itch Scale [NTIS]) and sleep disturbance/loss (using the Patient-Oriented Eczema Measure sleep item and SCORing AD Sleep Loss Visual Analog Scale) and, separately, between itch and work productivity (using the Work Productivity and Activity Impairment-Atopic Dermatitis Version 2.
Background: Abrocitinib improved signs and symptoms of moderate-to-severe atopic dermatitis (AD) at 12 or 16 weeks in phase 3 studies with a manageable safety profile. Further understanding of the abrocitinib long-term efficacy and safety profile is important for its appropriate use in treating chronic AD.
Objective: To evaluate the abrocitinib efficacy up to 48 weeks and long-term safety in patients with moderate-to-severe AD.